Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: a retrospective real-world analysis

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors. Patients who develop PDAC with locally advanced pancreatic cancer (LAPC) or metastases have an especially poor prognosis[1][1]. Although there have been improvements in systemic therapy, long-term disease control is